FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996633688> ?p ?o ?g. }

• W1996633688 endingPage "610" @default.
• W1996633688 startingPage "603" @default.
• W1996633688 abstract "Purpose To inform radiation treatment planning for clinically staged, node-negative bladder cancer patients by identifying clinical factors associated with the presence and location of occult pathologic pelvic lymph nodes. Methods and Materials The records of patients with clinically staged T1-T4N0 urothelial carcinoma of the bladder undergoing radical cystectomy and pelvic lymphadenectomy at a single institution were reviewed. Logistic regression was used to evaluate associations between preoperative clinical variables and occult pathologic pelvic or common iliac lymph nodes. Percentages of patient with involved lymph node regions entirely encompassed within whole bladder (perivesicular nodal region), small pelvic (perivesicular, obturator, internal iliac, and external iliac nodal regions), and extended pelvic clinical target volume (CTV) (small pelvic CTV plus common iliac regions) were calculated. Results Among 315 eligible patients, 81 (26%) were found to have involved pelvic lymph nodes at the time of surgery, with 38 (12%) having involved common iliac lymph nodes. Risk of occult pathologically involved lymph nodes did not vary with clinical T stage. On multivariate analysis, the presence of lymphovascular invasion (LVI) on preoperative biopsy was significantly associated with occult pelvic nodal involvement (odds ratio 3.740, 95% confidence interval 1.865-7.499, P<.001) and marginally associated with occult common iliac nodal involvement (odds ratio 2.307, 95% confidence interval 0.978-5.441, P=.056). The percentages of patients with involved lymph node regions entirely encompassed by whole bladder, small pelvic, and extended pelvic CTVs varied with clinical risk factors, ranging from 85.4%, 95.1%, and 100% in non-muscle-invasive patients to 44.7%, 71.1%, and 94.8% in patients with muscle-invasive disease and biopsy LVI. Conclusions Occult pelvic lymph node rates are substantial for all clinical subgroups, especially patients with LVI on biopsy. Extended coverage of pelvic lymph nodes up to the level of the common iliac nodes may be warranted in subsets of patients. To inform radiation treatment planning for clinically staged, node-negative bladder cancer patients by identifying clinical factors associated with the presence and location of occult pathologic pelvic lymph nodes. The records of patients with clinically staged T1-T4N0 urothelial carcinoma of the bladder undergoing radical cystectomy and pelvic lymphadenectomy at a single institution were reviewed. Logistic regression was used to evaluate associations between preoperative clinical variables and occult pathologic pelvic or common iliac lymph nodes. Percentages of patient with involved lymph node regions entirely encompassed within whole bladder (perivesicular nodal region), small pelvic (perivesicular, obturator, internal iliac, and external iliac nodal regions), and extended pelvic clinical target volume (CTV) (small pelvic CTV plus common iliac regions) were calculated. Among 315 eligible patients, 81 (26%) were found to have involved pelvic lymph nodes at the time of surgery, with 38 (12%) having involved common iliac lymph nodes. Risk of occult pathologically involved lymph nodes did not vary with clinical T stage. On multivariate analysis, the presence of lymphovascular invasion (LVI) on preoperative biopsy was significantly associated with occult pelvic nodal involvement (odds ratio 3.740, 95% confidence interval 1.865-7.499, P<.001) and marginally associated with occult common iliac nodal involvement (odds ratio 2.307, 95% confidence interval 0.978-5.441, P=.056). The percentages of patients with involved lymph node regions entirely encompassed by whole bladder, small pelvic, and extended pelvic CTVs varied with clinical risk factors, ranging from 85.4%, 95.1%, and 100% in non-muscle-invasive patients to 44.7%, 71.1%, and 94.8% in patients with muscle-invasive disease and biopsy LVI. Occult pelvic lymph node rates are substantial for all clinical subgroups, especially patients with LVI on biopsy. Extended coverage of pelvic lymph nodes up to the level of the common iliac nodes may be warranted in subsets of patients." @default.
• W1996633688 created "2016-06-24" @default.
• W1996633688 creator A5003720954 @default.
• W1996633688 creator A5008681368 @default.
• W1996633688 creator A5010567058 @default.
• W1996633688 creator A5031494172 @default.
• W1996633688 creator A5035439869 @default.
• W1996633688 creator A5039722276 @default.
• W1996633688 creator A5040742979 @default.
• W1996633688 creator A5042996985 @default.
• W1996633688 creator A5043322306 @default.
• W1996633688 creator A5043470257 @default.
• W1996633688 creator A5055949265 @default.
• W1996633688 creator A5066133616 @default.
• W1996633688 date "2014-03-01" @default.
• W1996633688 modified "2023-10-16" @default.
• W1996633688 title "Occult Pelvic Lymph Node Involvement in Bladder Cancer: Implications for Definitive Radiation" @default.
• W1996633688 cites W1560239325 @default.
• W1996633688 cites W1606684848 @default.
• W1996633688 cites W1788729872 @default.
• W1996633688 cites W1975246874 @default.
• W1996633688 cites W1983690825 @default.
• W1996633688 cites W2004878460 @default.
• W1996633688 cites W2028376685 @default.
• W1996633688 cites W2049710699 @default.
• W1996633688 cites W2056247168 @default.
• W1996633688 cites W2072978161 @default.
• W1996633688 cites W2091670068 @default.
• W1996633688 cites W2095027266 @default.
• W1996633688 cites W2108546094 @default.
• W1996633688 cites W2164361265 @default.
• W1996633688 cites W2170196859 @default.
• W1996633688 cites W2171486331 @default.
• W1996633688 cites W2412417609 @default.
• W1996633688 doi "https://doi.org/10.1016/j.ijrobp.2013.11.211" @default.
• W1996633688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24411628" @default.
• W1996633688 hasPublicationYear "2014" @default.
• W1996633688 type Work @default.
• W1996633688 sameAs 1996633688 @default.
• W1996633688 citedByCount "30" @default.
• W1996633688 countsByYear W19966336882014 @default.
• W1996633688 countsByYear W19966336882015 @default.
• W1996633688 countsByYear W19966336882016 @default.
• W1996633688 countsByYear W19966336882017 @default.
• W1996633688 countsByYear W19966336882018 @default.
• W1996633688 countsByYear W19966336882020 @default.
• W1996633688 countsByYear W19966336882021 @default.
• W1996633688 countsByYear W19966336882022 @default.
• W1996633688 countsByYear W19966336882023 @default.
• W1996633688 crossrefType "journal-article" @default.
• W1996633688 hasAuthorship W1996633688A5003720954 @default.
• W1996633688 hasAuthorship W1996633688A5008681368 @default.
• W1996633688 hasAuthorship W1996633688A5010567058 @default.
• W1996633688 hasAuthorship W1996633688A5031494172 @default.
• W1996633688 hasAuthorship W1996633688A5035439869 @default.
• W1996633688 hasAuthorship W1996633688A5039722276 @default.
• W1996633688 hasAuthorship W1996633688A5040742979 @default.
• W1996633688 hasAuthorship W1996633688A5042996985 @default.
• W1996633688 hasAuthorship W1996633688A5043322306 @default.
• W1996633688 hasAuthorship W1996633688A5043470257 @default.
• W1996633688 hasAuthorship W1996633688A5055949265 @default.
• W1996633688 hasAuthorship W1996633688A5066133616 @default.
• W1996633688 hasConcept C121608353 @default.
• W1996633688 hasConcept C126322002 @default.
• W1996633688 hasConcept C126838900 @default.
• W1996633688 hasConcept C141071460 @default.
• W1996633688 hasConcept C142724271 @default.
• W1996633688 hasConcept C156957248 @default.
• W1996633688 hasConcept C204787440 @default.
• W1996633688 hasConcept C2775910329 @default.
• W1996633688 hasConcept C2777546739 @default.
• W1996633688 hasConcept C2779720271 @default.
• W1996633688 hasConcept C2780352672 @default.
• W1996633688 hasConcept C2780849966 @default.
• W1996633688 hasConcept C520017518 @default.
• W1996633688 hasConcept C71924100 @default.
• W1996633688 hasConceptScore W1996633688C121608353 @default.
• W1996633688 hasConceptScore W1996633688C126322002 @default.
• W1996633688 hasConceptScore W1996633688C126838900 @default.
• W1996633688 hasConceptScore W1996633688C141071460 @default.
• W1996633688 hasConceptScore W1996633688C142724271 @default.
• W1996633688 hasConceptScore W1996633688C156957248 @default.
• W1996633688 hasConceptScore W1996633688C204787440 @default.
• W1996633688 hasConceptScore W1996633688C2775910329 @default.
• W1996633688 hasConceptScore W1996633688C2777546739 @default.
• W1996633688 hasConceptScore W1996633688C2779720271 @default.
• W1996633688 hasConceptScore W1996633688C2780352672 @default.
• W1996633688 hasConceptScore W1996633688C2780849966 @default.
• W1996633688 hasConceptScore W1996633688C520017518 @default.
• W1996633688 hasConceptScore W1996633688C71924100 @default.
• W1996633688 hasIssue "3" @default.
• W1996633688 hasLocation W19966336881 @default.
• W1996633688 hasLocation W19966336882 @default.
• W1996633688 hasOpenAccess W1996633688 @default.
• W1996633688 hasPrimaryLocation W19966336881 @default.
• W1996633688 hasRelatedWork W1989626086 @default.
• W1996633688 hasRelatedWork W1991861304 @default.
• W1996633688 hasRelatedWork W1992115187 @default.

• next